FEB 15, 2018 09:00 AM PST

What is a CAR-T cell therapy?


Most people must have heard revolutionary cancer therapy called CAR-T cell therapy, a kind of cancer immunotherapy. It has changed the landscape of cancer therapy and has the potential of curing some of the chemotherapy refractory blood cancer such as acute lymphoblastic leukemia (ALL).
Cancer immunotherapy is not a very new science, but it is the culmination of cumulative knowledge gained through countless experiments in immunology and cancer. In 1893, William Coley's observed reduction in tumor size upon injection of streptococcus bacteria. Giving BCG vaccine in early stage of bladder cancer is a form of oldest cancer immunotherapy which is still used in clinical practice.
T cells are the type of a white blood cell which plays an essential role in mounting an appropriate immune response to either diseased cells (virus-infected or cancer cells) or foreign pathogens. Cytotoxic T cells are central in killing cancerous cells. They recognize cancer cells through a particular receptor called T cell receptor (TCR) which binds to the novel antigen expressed only on cancer cells and thereby killing them. However, cytotoxic T cell which can recognize unique tumor antigen is scarce in number, or sometimes tumor itself create microenvironment to decrease their frequency around the tumor microenvironment. One way to overcome this challenge is to engineer T cells ex-vivo isolated from either blood of the patient or healthy individual. In this method, T cells are engineered to produce a single chain variable fragment of an antibody (chimeric antigen receptor; CAR) which recognizes unique antigen only expressed onto tumor cells, e.g., CD19 in case of ALL. They are expended in large number ex-vivo and injected into the patient, where further proliferation produces more engineered T cells specific to tumor cells. Expended CAR-T cells lead to complete killing of all tumor cells without harming healthy normal cells, unlike conventional cancer treatment where most of the side effects come from the killing of healthy cells. However, there are some challenges associated with CAR-T cell therapy such as cytokine storm and expensive nature of its production. Moreover, they are not currently suitable for solid tumors which constitute the majority of cancer found among the population.
FDA has recently approved two CAR-T cell therapy based on CD19 chimeric antigen receptor to treat ALL and diffuse large B cell lymphoma.
About the Author
  • Biological research scientist by profession with passion to write about science in general.
You May Also Like
SEP 22, 2018
Videos
SEP 22, 2018
How Much of the Human Genome is Just Junk DNA?
Once written off as junk, it was suggested that some regions of the genome that don't code for protein act as regulators. But how much?...
OCT 01, 2018
Videos
OCT 01, 2018
Is Bigger Better?
Bigger is better, right? If you’re trying to insult someone you might call them a “pea brain” or tell them they have a “bird brain,...
OCT 02, 2018
Videos
OCT 02, 2018
Learning how Bacterial Chemicals Impact Human Health
We play host to a huge number of microbes, and all the chemicals that they produce....
OCT 08, 2018
Technology
OCT 08, 2018
The SolarFlower is a Promising New Take on Solar Energy
Solar energy is a clean and renewable energy source with promising applications in the near future as solar panel technology matures. SmartFlower is an int...
OCT 09, 2018
Videos
OCT 09, 2018
Take-out doesn't have to be this way
I love take-out just as much as the next person, but there's something that gets to me every time I order in: the amount of single-use waste that comes...
OCT 11, 2018
Videos
OCT 11, 2018
An Inexpensive Kit Teaches Kids About Molecular Biology
Biology is advancing at a rapid pace. Students will be ready for those advances if they can learn about cutting-edge concepts at an early age....
Loading Comments...